abrocitinib

Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib
Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib
Endpoints
Pfizer
JAK inhibitors
abrocitinib
Dupixent
atopic dermatitis
clinical trials
Flag link:
Pfizer may have a lot going on in immunology, but all its drugs could be beaten by rivals: analyst
Pfizer may have a lot going on in immunology, but all its drugs could be beaten by rivals: analyst
Fierce Pharma
Pfizer
immunology
abrocitinib
Xeljanz
PF-06651600
Flag link:
Pfizer's JAK abrocitinib comes through in teen eczema test
Pfizer's JAK abrocitinib comes through in teen eczema test
Fierce Biotech
Pfizer
abrocitinib
eczema
atopic dermatitis
clinical trials
Flag link:
New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema
New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema
Endpoints
Pfizer
abrocitinib
Dupixent
clinical trials
eczema
Flag link:
Pfizer Posts Positive Results in Two Phase III Studies, Postpones Investor Day
Pfizer Posts Positive Results in Two Phase III Studies, Postpones Investor Day
BioSpace
Pfizer
clinical trials
atopic dermatitis
pneumococcal disease
20VPnC
vaccines
abrocitinib
Flag link:
Upcoming events – Pfizer's abrocitinib and Myovant's relugolix
Upcoming events – Pfizer's abrocitinib and Myovant's relugolix
EP Vantage
Pfizer
abrocitinib
Dupixent
Sanofi
Myovant
Relugolix
uterine fibroids
Flag link:
Pfizer posts detailed phase 3 data on its Dupixent rival
Pfizer posts detailed phase 3 data on its Dupixent rival
Fierce Biotech
Pfizer
clinical trials
atopic dermatitis
abrocitinib
Dupixent
Sanofi
Regeneron
Flag link:
Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug
Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug
TheStreet.com
Pfizer
clinical trials
eczema
abrocitinib
Flag link:
Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large
Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large
Endpoints
Pfizer
JAK inhibitors
abrocitinib
anti-inflammatories
Flag link: